PF-4950834

Cat. No.:	HY-122011
CAS No.:	1256264-62-6
Molecular Formula:	$C_{21}H_{19}N_3O_2$
Molecular Weight:	345.39
Target:	ROCK; SGK; PKA; PKC
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PF-4950834 is a potent, selective, orally bioavailable, ATP-competitive rho kinase inhibitor with IC_{50} values of 8.35 nM and 33.12 nM against ROCK2 and ROCK1, respectively. PF-4950834 inhibits neutrophil migration[1].			
IC_{50} & Target	ROCK2 8.35 nM (IC_{50})	ROCK1 33.12 nM (IC_{50})	PKA 424 nM (IC_{50})	PKCη 756 nM (IC_{50})
In Vitro	PF-4950834 shows inhibition against the AGC (cAMP-dependent protein kinase/protein kinase G/protein kinase C) kinase family with IC_{50} values of 8.35, 33.12, 102, 216, 321, 384, 411, 424, 457, 578, 736, 756 and 2900 nM for ROCK2, ROCK1, PRKG1, PKN1, SGK2, PRKG2, MSK1, PKA, PRKX, MSK2, P70S6K, PKC_{η} and SGK1, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES

[1]. Rajagopalan LE, et al. Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activity. J Pharmacol Exp Ther. 2010 Jun;333(3):707-16.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA